Hawthorn Pharma Services

Titan Grove has committed equity capital to Hawthorn Pharma Services to support its acquisition activities. Hawthorn is seeking to invest in North American businesses that are ENDURING in nature active in the following industries:

CLINICAL
TRIAL SITES
LABORATORY INFORMATION MANAGEMENT pharma- covigilance SPECIALTY SERVICES
Focus
Areas
  • FDA-regulated sites for Phase II-IV trials
  • Technology enabled information management systems for laboratories
  • Drug safety collection, detection, assessment, monitoring and prevention practices
  • Multi-channel
    digital marketing
  • Contract manufacturing for prescription drugs, OTC, and biologics
  • Translation services
  • Regulatory support
Investment Thesis
  • Increased regulatory scrutiny and oversight
  • More complex clinical research
  • Focus on more complex disease states
  • Progressively informed customers
  • Personalized medicine
  • Chronic conditions treatment
  • Continuous pricing pressure
  • Industry globalization
Investment Criteria
  • Control-oriented transactions in small-to-middle market companies
  • Broad range of transactions in situations where catalysts can increase long-term value
  • Annual operating profit in the range of $2-25 million
  • Equity investment of $5-50 million
  • Sustainable operating margins in excess of 10%

We are particularly adept at complex or difficult situations, where our permanent capital advantage, flexibility and broad capabilities can make a significant difference to our partners in enacting meaningful change in the financial or operational profile of the businesses in which we invest.